Revenue for the fiscal third quarter of 2009 was $75.31 million, an increase of 12%, compared to $67.03 million for the prior-year period.
For the first nine months of fiscal 2009, revenue was $221.51 million, compared with $192.58 million in the prior-year period. Net income was $56.75 million, or $0.80 per fully diluted share, for the nine months ended February 28, 2009, compared with $53.18 million, or $0.75 per fully diluted share, for the nine months ended February 29, 2008.
Gioacchino De Chirico, Immucor’s president and CEO, said: “We are pleased with the stability of our performance given the current economic environment. The demand for our reagent products, which account for nearly 90% of our total revenue, has remained stable as shown by our earnings and our cash flow.”